Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Life Health Products' silver acetate

Executive Summary

Studies in smoking cessation and relapse prevention are "well designed," but sample sizes are too small to yield conclusive evidence of efficacy, FDA told the company in a July 20 letter. In March, the company submitted four study proposals to FDA for its 2.5 mg lozenge silver acetate product. FDA said that the studies can be "considered pilot studies and the investigators can obtain preliminary evidence of efficacy".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel